FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973035724> ?p ?o ?g. }

• W1973035724 endingPage "S53" @default.
• W1973035724 startingPage "S38" @default.
• W1973035724 abstract "Treating breast cancer under the constraints of significantly limited health care resources poses unique challenges that are not well addressed by existing guidelines. We present evidence-based guidelines for systematically prioritizing cancer therapies across the entire spectrum of resource levels. After consideration of factors affecting the value of a given breast cancer therapy (contribution to overall survival, disease-free survival, quality of life, and cost), we assigned each therapy to one of four incremental levels--basic, limited, enhanced, or maximal--that together map out a sequential and flexible approach for planning, establishing, and expanding breast cancer treatment services. For stage I disease, basic-level therapies are modified radical mastectomy and endocrine therapy with ovarian ablation or tamoxifen; therapies added at the limited level are breast-conserving therapy, radiation therapy, and standard-efficacy chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil [CMF], or doxorubicin and cyclophosphamide [AC], epirubicin and cyclophosphamide [EC], or 5-fluorouracil, doxorubicin, and cyclophosphamide [FAC]); at the enhanced level, taxane chemotherapy and endocrine therapy with aromatase inhibitors or luteinizing hormone-releasing hormone (LH-RH) agonists; and at the maximal level, reconstructive surgery, dose-dense chemotherapy, and growth factors. For stage II disease, the therapy allocation is the same, with the exception that standard-efficacy chemotherapy is a basic-level therapy. For locally advanced breast cancer, basic-level therapies are modified radical mastectomy, neoadjuvant chemotherapy (CMF, AC, or FAC), and endocrine therapy with ovarian ablation or tamoxifen; the therapy added at the limited level is postmastectomy radiation therapy; at the enhanced level, breast-conserving therapy, breast-conserving whole-breast radiation therapy, taxane chemotherapy, and endocrine therapy with aromatase inhibitors or LH-RH agonists; and at the maximal level, reconstructive surgery and dose-dense chemotherapy and growth factors. For metastatic or recurrent disease, basic-level therapies are total mastectomy for ipsilateral in-breast recurrence, endocrine therapy with ovarian ablation or tamoxifen, and analgesics; therapies added at the limited level are radiation therapy and CMF or anthracycline chemotherapy; at the enhanced level, chemotherapy with taxanes, capecitabine, or trastuzumab, endocrine therapy with aromatase inhibitors, and bisphosphonates; and at the maximal level, chemotherapy with vinorelbine, gemcitabine, or carboplatin, growth factors, and endocrine therapy with fulvestrant. Compared with the treatment of early breast cancer, the treatment of advanced breast cancer is more resource intensive and generally has poorer outcomes, highlighting the potential benefit of earlier detection and diagnosis, both in terms of conserving scarce resources and in terms of reducing morbidity and mortality. Use of the scheme outlined here should help ministers of health, policymakers, administrators, and institutions in limited-resource settings plan, establish, and gradually expand breast cancer treatment services for their populations." @default.
• W1973035724 created "2016-06-24" @default.
• W1973035724 creator A5011608816 @default.
• W1973035724 creator A5018221400 @default.
• W1973035724 creator A5018617106 @default.
• W1973035724 creator A5019412832 @default.
• W1973035724 creator A5022249692 @default.
• W1973035724 creator A5031075467 @default.
• W1973035724 creator A5034779816 @default.
• W1973035724 creator A5039711199 @default.
• W1973035724 creator A5060585210 @default.
• W1973035724 creator A5063822600 @default.
• W1973035724 date "2006-01-01" @default.
• W1973035724 modified "2023-09-30" @default.
• W1973035724 title "Breast Cancer in Limited-Resource Countries: Treatment and Allocation of Resources" @default.
• W1973035724 cites W1262485082 @default.
• W1973035724 cites W1525318852 @default.
• W1973035724 cites W1562190372 @default.
• W1973035724 cites W1892496998 @default.
• W1973035724 cites W1918705397 @default.
• W1973035724 cites W1930298597 @default.
• W1973035724 cites W1936081012 @default.
• W1973035724 cites W1970797634 @default.
• W1973035724 cites W1973764566 @default.
• W1973035724 cites W1974701860 @default.
• W1973035724 cites W1982853521 @default.
• W1973035724 cites W1986716273 @default.
• W1973035724 cites W1987537831 @default.
• W1973035724 cites W1987897297 @default.
• W1973035724 cites W2001589762 @default.
• W1973035724 cites W2006455673 @default.
• W1973035724 cites W2010164469 @default.
• W1973035724 cites W2011705265 @default.
• W1973035724 cites W2019075819 @default.
• W1973035724 cites W2019582591 @default.
• W1973035724 cites W2061839701 @default.
• W1973035724 cites W2067420088 @default.
• W1973035724 cites W2071205059 @default.
• W1973035724 cites W2099351704 @default.
• W1973035724 cites W2101881391 @default.
• W1973035724 cites W2104828918 @default.
• W1973035724 cites W2107769390 @default.
• W1973035724 cites W2108180382 @default.
• W1973035724 cites W2110934536 @default.
• W1973035724 cites W2114167623 @default.
• W1973035724 cites W2122761438 @default.
• W1973035724 cites W2124061625 @default.
• W1973035724 cites W2124924898 @default.
• W1973035724 cites W2126511903 @default.
• W1973035724 cites W2128100826 @default.
• W1973035724 cites W2129686798 @default.
• W1973035724 cites W2132434084 @default.
• W1973035724 cites W2133764807 @default.
• W1973035724 cites W2135800076 @default.
• W1973035724 cites W2136802843 @default.
• W1973035724 cites W2138652241 @default.
• W1973035724 cites W2138734774 @default.
• W1973035724 cites W2145486963 @default.
• W1973035724 cites W2149455283 @default.
• W1973035724 cites W2151128729 @default.
• W1973035724 cites W2151225161 @default.
• W1973035724 cites W2151447010 @default.
• W1973035724 cites W2153247110 @default.
• W1973035724 cites W2162760540 @default.
• W1973035724 cites W2163688875 @default.
• W1973035724 cites W2163910197 @default.
• W1973035724 cites W2163988169 @default.
• W1973035724 cites W2164208758 @default.
• W1973035724 cites W2166003148 @default.
• W1973035724 cites W2168517539 @default.
• W1973035724 cites W2332829713 @default.
• W1973035724 cites W2343407300 @default.
• W1973035724 cites W2800860148 @default.
• W1973035724 cites W3128877721 @default.
• W1973035724 cites W3146187270 @default.
• W1973035724 cites W4210716851 @default.
• W1973035724 cites W4233446420 @default.
• W1973035724 cites W4234837271 @default.
• W1973035724 cites W4236203212 @default.
• W1973035724 cites W4237434210 @default.
• W1973035724 cites W4237553706 @default.
• W1973035724 cites W4239180165 @default.
• W1973035724 cites W4249369842 @default.
• W1973035724 cites W4293107555 @default.
• W1973035724 cites W4362046093 @default.
• W1973035724 doi "https://doi.org/10.1111/j.1075-122x.2006.00202.x" @default.
• W1973035724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16430398" @default.
• W1973035724 hasPublicationYear "2006" @default.
• W1973035724 type Work @default.
• W1973035724 sameAs 1973035724 @default.
• W1973035724 citedByCount "70" @default.
• W1973035724 countsByYear W19730357242012 @default.
• W1973035724 countsByYear W19730357242013 @default.
• W1973035724 countsByYear W19730357242014 @default.
• W1973035724 countsByYear W19730357242015 @default.
• W1973035724 countsByYear W19730357242016 @default.
• W1973035724 countsByYear W19730357242017 @default.
• W1973035724 countsByYear W19730357242018 @default.

• next